Gene therapy for deafness: 5-Year safety watch begins
NCT ID NCT06696456
Summary
This study follows 30 people for up to five years after they received an experimental gene therapy for hearing loss. The goal is to monitor for any long-term safety issues and see if the treatment's benefits last. Participants had a specific type of genetic hearing loss and received the therapy in a previous trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTOFERLIN GENE-MEDIATED HEARING LOSS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19146, United States
-
Hospital Sant Joan de Déu
Esplugues de Llobregat, Barcelona, 08950, Spain
-
National Taiwan University Hospital
Taipei, Taiwan, (R.O.C), 100, Taiwan
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.